LON:ONC Oncimmune (ONC) Share Price, News & Analysis GBX 10.45 -0.05 (-0.48%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 10.22▼ 10.4550-Day Range 9.58▼ 2652-Week Range 9.35▼ 31Volume2,839 shsAverage Volume88,274 shsMarket Capitalization£7.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsInsider TradesStock AnalysisChartCompetitorsInsider Trades Get Oncimmune alerts: Email Address Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About Oncimmune Stock (LON:ONC)Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.Read More ONC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONC Stock News HeadlinesMay 26, 2024 | finance.yahoo.comAnalysts Expect Breakeven For Oncimmune Holdings plc (LON:ONC) Before LongMay 21, 2024 | lse.co.ukEARNINGS AND TRADING: Topps Tiles in strategic shift as swings to lossJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 17, 2024 | investing.comOncimmune Holdings PLC (ONCON)March 19, 2024 | wsj.comOncimmune Holdings PLCMarch 2, 2024 | finance.yahoo.comOncimmune Holdings Full Year 2023 Earnings: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)February 15, 2024 | reuters.comCancer test firm Freenome raises $254 mln in fresh fundingFebruary 14, 2024 | msn.comActivist investor Kelso gains board seats at The Works as it tries to enhance shareholder valueJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.December 2, 2023 | proactiveinvestors.com.auOncimmune seeing commercial traction as it inks new deals with big pharma companiesSeptember 26, 2023 | yahoo.comThe Unique Use of Liquid BiopsyAugust 1, 2023 | marketwatch.comOncimmune's Acting CEO Ron Kirschner Steps Down, Takes COO Role; Gouldstone Starts as CEOJuly 14, 2023 | marketwatch.comOncimmune Shares Fall As Company Lowers FY 2022 Revenue ResultJuly 12, 2023 | lse.co.ukOncimmune names chief executive successor, while finance chief leavesJuly 12, 2023 | marketwatch.comOncimmune Holdings Appoints Martin Gouldstone CEO; CFO Matthew Hall to Step DownJune 23, 2023 | lse.co.ukOncimmune Holdings shakes up leadership and unveils new growth planJune 23, 2023 | marketwatch.comOncimmune CEO Adam Hill to Step Down; Sees Tough End to FY 2023May 31, 2023 | lse.co.ukOncimmune shares plummet as interim revenue falls by fifthSee More Headlines Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2018Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ONC CUSIPN/A CIKN/A Weboncimmune.com Phone+44-115-8231869FaxN/AEmployees52Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.03) Trailing P/E RatioN/A Forward P/E Ratio10.57 P/E GrowthN/ANet Income£-6,150,000.00 Net Margins356.25% Pretax MarginN/A Return on Equity-760.96% Return on Assets-26.38% Debt Debt-to-Equity Ratio806.85 Current Ratio3.91 Quick Ratio0.63 Sales & Book Value Annual Sales£1.15 million Price / Sales6.74 Cash FlowGBX 0.87 per share Price / Cash Flow11.96 Book ValueGBX 1 per share Price / Book10.45Miscellaneous Outstanding Shares74,140,000Free FloatN/AMarket Cap£7.75 million OptionableNot Optionable Beta1.09 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Martin John Gouldstone (Age 58)CEO & Director Mr. Martin HudsonFinance DirectorMr. Ron Kirschner (Age 45)COO, General Counsel & Company Secretary Prof. Tariq Sethi B.Sc.FRCP, M.A., M.D., Ph.D., Chief Scientific OfficerMs. Cléa RosenfeldHead of Investor RelationsMr. Maarten BrusseChief Commercial Officer of AsiaMore ExecutivesKey CompetitorsCollagen Solutions plc (COS.L)LON:COSC4X DiscoveryLON:C4XD4D pharmaLON:DDDDArecor TherapeuticsLON:ARECOxford BioDynamicsLON:OBDView All CompetitorsInsidersMartin GouldstoneBought 36,023 shares on 12/8/2023Total: £972,621.00 ($27.00/share)View All Insider Transactions ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncimmune's stock was trading at GBX 25.20 at the beginning of the year. Since then, ONC shares have decreased by 58.5% and is now trading at GBX 10.45. View the best growth stocks for 2024 here. How were Oncimmune's earnings last quarter? Oncimmune Holdings plc (LON:ONC) released its earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share (EPS) for the quarter. The business had revenue of $0.08 million for the quarter. Oncimmune had a net margin of 356.25% and a negative trailing twelve-month return on equity of 760.96%. How do I buy shares of Oncimmune? Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM). This page (LON:ONC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.